Timed topical dexamethasone eye drops improve mitochondrial function to prevent severe retinopathy of prematurity.
Ontology highlight
ABSTRACT: Pathological neovascularization in retinopathy of prematurity (ROP) can cause visual impairment in preterm infants. Current ROP treatments which are not preventative and only address late neovascular ROP, are costly and can lead to severe complications. We showed that topical 0.1% dexamethasone eye drops administered prior to peak neovessel formation prevented neovascularization in five extremely preterm infants at high risk for ROP and suppressed neovascularization by 30% in mouse oxygen-induced retinopathy (OIR) modeling ROP. In contrast, in OIR, topical dexamethasone treatment before any neovessel formation had limited efficacy in preventing later neovascularization, while treatment after peak neovessel formation had a non-statistically significant trend to exacerbating disease. Optimal
SUBMITTER: Yagi H
PROVIDER: S-EPMC11564262 | biostudies-literature | 2024 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA